一场双向奔赴。 作者 I 杨文静 报道 I 投资界PEdaily 大湾区创投圈更热闹了。 最新一幕是3月2 8日，前海深港青年梦工场基金（简称"梦工场基金"）宣布首批出资——基金管理方弘毅投资与两家子基金管理机构、 以及两家落地前海梦工场的初创企业签约。 这是深港联手培育大湾区科创生态的新尝试。弘毅投资总裁曹永刚透露，梦工场基金不仅提供资金，更将依托弘毅投资成长型企业和并 购的经验，利用积累的头部企业和链主企业资源为投资项目构建产业生态圈，打造大湾区早期科创生态崭新一幕。 一幅深港融合的蓝图正在徐徐铺开。 一次新尝试 一切要追溯到一年前。 彼时，前海管理局提出打造梦工场" 1 5 1 0 "发展模式，为香港青年在创新创业领域提供支持，其中就包括出资组建一支基金，直面港企 港人创新创业最关键、最迫切需求。 以"前海所有"，应"香港所需" ——梦工场基金肩负着这样的使命应运而生。 经过遴选，梦工场基金最终选定与前海有着深厚渊源、且兼具产融结合背景的弘毅投资作为管理人。今年2月，梦工场基金正式成立， 首期规模5亿元，主要由前海产业引导基金出资， 近期也会在香港发行一只母基金。 投资界了解到，这是弘毅投资管理的第一支 ...

园山品牌LOHO联合闪极推出的AI"拍拍镜"。 眼镜也可以成为你的"私人助理"!只需语音唤醒，就能随时用第一视角拍摄照片和视频；即便是几天前 的会议记录，一句话的事儿就可以让其轻松整理；遇到看不懂的外文，让眼镜即时翻译，同步播报给 你；到了陌生地方不知道有啥好吃的，问眼镜就行……这款产自龙岗园山的AI智能"拍拍镜"，自去年12 月发布，就迅速火爆，几分钟内便订出去5万副。经过3个多月的调试，近日，这款聪明的眼镜将开放线 下门店体验。园山是深圳眼镜产业生产制造聚集地。种种迹象表明，自2024年开始，这里的眼镜制造厂 商正加速冲上AI赛道。凭借超前的眼光和深厚的产业基础，园山眼镜企业将在AI眼镜的蓝海里闯出一 片天。 首款量产AI眼镜产自园山 LOHO是国内眼镜快时尚头部品牌。上文提到的AI智能"拍拍镜"，就是由LOHO与国内储能明星企业闪 极科技联合发布。这款眼镜，也被认为是首款量产的AI眼镜。 50克的重量，30多克的体感重量，看起来并不算粗的镜框，让这副"很有内涵"的智能眼镜看起来跟普通 眼镜区别不大。LOHO创始人黄心仲介绍，现在市面上发布的AI眼镜数量不少，能够实现的功能也很 多，但为什么没有流行起来， ...

Core Viewpoint - The Shanghai Stock Exchange (SSE) is actively conducting a large-scale research initiative on private enterprises, focusing on how these companies are embracing artificial intelligence (AI) technology to enhance their operations and competitiveness [1][2]. Group 1: AI Integration in Private Enterprises - Private enterprises listed on the Shanghai Stock Exchange are proactively integrating AI technologies, with companies like Fosun Pharma leveraging global leading AI models to enhance drug development processes [4]. - Fosun Pharma has launched the PharmAID decision-making AI platform, which addresses various challenges in drug research, including literature review and market analysis [4]. - Dragon Flag Technology is focusing on AI/AR smart glasses as a key growth area, indicating a significant shift towards AI-driven products in the consumer electronics sector [5][6]. Group 2: Research and Development Insights - The SSE's research initiative aims to identify the main challenges faced by private enterprises and explore how capital market tools can help overcome these obstacles [2][9]. - Companies have expressed the need for expanded AI databases and reduced financing costs to enhance AI applications in their operations [9]. - Fosun Pharma's Vice Chairman highlighted the necessity of increasing data volume for effective AI training in drug development [9]. Group 3: Growth of Private Enterprises in Shanghai - Private enterprises constitute over 50% of the companies listed on the Shanghai Stock Exchange, with a total market value of approximately 14 trillion yuan [12]. - In the first three quarters of 2024, private enterprises in Shanghai achieved a revenue of 5.37 trillion yuan, with a compound annual growth rate of 8.7% over the past three years [12]. - The investment in R&D by these enterprises reached 193.5 billion yuan, reflecting a compound annual growth rate of 13.4% [12].